a Objectives: To determine the incidence of fracture among aging HIV-infected (HIVþ) and uninfected men (HIVÀ). To evaluate factors independently associated with fracture risk.
Introduction
Osteopenia and osteoporosis are more prevalent in HIV-infected (HIVþ) men and women compared with HIV-uninfected (HIVÀ) controls [1] , and young HIVþ individuals are also at higher risk of bone loss [2] [3] [4] . Low bone mineral density (BMD) translates into a higher risk of fracture [5, 6] that is higher in HIVþ individuals. Triant et al. [7] reported higher prevalence of vertebral, hip and wrist fractures in HIVþ men and higher prevalence of vertebral and wrist fractures in HIVþ women compared with HIVÀ controls. Higher rates of fracture in young HIVþ men have been previously reported [3, 7] , whereas studies in young HIVþ women have shown conflicting results [8, 9] . Among HIVþ patients, several risk factors have been associated with bone loss and higher incidence of fracture, including traditional risk factors such as age, sex, race, BMI, smoking, alcohol and drug use [10, 11] , HIV-specific factors [3, [12] [13] [14] [15] and specific antiretroviral therapy (ART) agents, especially protease inhibitors and tenofovir disoproxil fumarate (TDF) containing combinations [15] [16] [17] [18] . Coinfection with hepatitis C virus (HCV) increased fracture risk in several reports [3] , whereas others found no association [9] .
Early screening for fracture risk in HIVþ individuals has been recommended [19, 20] , but the exact age when screening should start remains controversial. There is still extensive variation in the approach to screening for osteoporosis in HIVþ, not only in the United States of America but also worldwide [21] .
In this study, we aimed to compare the incidence of fracture in HIVþ with HIVÀ men who participated in the Multicenter AIDS Cohort Study (MACS) and to determine the predictors of fracture. Our a-priori hypothesis was that HIV modified the effect of age on fractures.
Methods

Study population
The MACS is an ongoing, prospective multicenter cohort study of the natural and treated history of HIV infection in men. As of March 2015, 3898 HIVþ and 3439 HIVÀ MSM had been enrolled [1984] [1985] . MACS design and methods have been described previously [22] [23] [24] . In brief, at each semiannual study visit, participants complete a standardized questionnaire soliciting information about their medical history, HIV treatment, behaviors, depression and daily activities; undergo physical examinations and have blood and urine specimens collected for laboratory testing and storage [25] . Study questionnaires are available at http://aidscohortstudy.org/. Informed consent was obtained from all participants. Study protocols were approved by the Institutional Review Boards at each study site.
Self-reported fracture data were extracted from the MACS database using The International Classification of Diseases, Ninth Revision, Clinical Modification codes. At visit 36 (in 2001) and all subsequent visits, participants were asked if they had any bone-related diagnoses, including any new broken or fractured bones since the last visit. In addition, in 2010 (visit 53 and 54), participants were asked retrospectively about personal history of fractures. A total of 2283 men responded to the historical questions at visit 53 and 54; 1935 men who were 40 years or older and had at least one follow-up visit were included. For men who did not respond to the historical questions, bone outcomes were ascertained in 1141 participants at and after visit 36. Of these, 865 men who were 40 years or older and had one additional visit were considered eligible for this study. The first MACS visit at which an individual came under observation for fracture outcomes was designated the index visit. HIVþ participants who never received ART before they were last seen in the MACS by March 2015 were excluded. The final study population included 2629 men.
Outcome: incident fracture In this study, we considered two self-reported fracture outcomes that occurred among men of 40 years and over: all fractures except for those occurring at the face, skull or digits and fragility fractures, defined as fractures at vertebral column, femur, wrist and humerus [26] .
Exposure of interest: age and HIV Self-reported date of birth was obtained at enrollment into the MACS. HIV seropositivity was determined using an ELISA confirmed by western blot. Standardized tests were used for measuring CD4 þ T-lymphocyte counts (cells/ml) (CD4 þ ) and plasma HIV-1 RNA concentrations.
Confounders
Race was obtained at enrollment into the MACS. Selfreported cigarette smoking and alcohol use, BMI, comorbidities, T-lymphocyte counts (cells/ml) (CD4 þ ) and plasma HIV-1 RNA concentrations were assessed at each semiannual visit. Estimated glomerular filtration rate (eGFR) in ml/min per 1.73 m 2 was calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation. HCV was determined by reactive HCV antibody or detectable plasma HCV RNA levels. Diabetes mellitus was defined as a fasting glucose at least 126 mg/dl or a self-reported diabetes diagnosis with the use of glucose-lowering medications. High blood pressure (BP) was defined as SBP at least 140 mmHg, DBP at least 90 mmHg or self-reported diagnosis with use of antihypertensive medication. Viremia copy-years (VCY) were calculated as the area under the viral load curve from the index visit or the first available viral load after seroconversion, whichever occurred later, by applying the trapezoidal rule [27] . Other HIV-specific factors that were considered include the history of AIDS diagnosis, any ART use and cumulative use of TDF and protease inhibitor per 5 years.
Statistical analyses
Demographic and clinical characteristics at the index visit were compared by HIV serostatus using Wilcoxon ranksum test for continuous variables and Fisher's exact test for categorical variables. Incident fracture was defined as the first self-reported fracture after age 40 while under observation for bone outcomes in the MACS. Individuals contributed person-time from the index visit to the time of incident fracture or the last time they were seen in MACS before 31 March 2015. Incidence rates were calculated as the number of new fractures (or fragility fractures) that occurred per 1000 person-years. Crude incidence rate ratio (IRR) and adjusted incident rate ratios (aIRR) and 95% confidence intervals ([,]) were estimated with Poisson regression models. To test the apriori hypothesis, a nested models approach with a likelihood ratio tests to determine the better fit (the model with or without the interaction term) was used. The final model included a test for interaction between HIV serostatus and age and adjustment for confounders: race, BMI, hypertension, diabetes, HCV, eGFR, smoking and alcohol use. We also explored the associations between fractures and HIV-related factors including CD4 þ T-cell count and plasma HIV-1 RNA level at index visit, VCY, ART use (time updated), AIDS diagnosis prior to index visit, and cumulative use of TDF and protease inhibitors among the HIV-infected men. Missing predictor data were handled by multiple imputation using the Markov Chain Monte Carlo methods. Ten imputations were carried out for the entire study population and after stratification by HIV serostatus. A P value less than 0.05 guided statistical interpretation. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina, USA). Plots were produced using R statistical software.
Results
Participant characteristics at index visit
The study population included 1221 HIVþ and 1408 HIVÀ men (Table 1 ). The two groups were similar with respect to age, BMI, eGFR and moderate/heavy alcohol consumption. The presence of comorbidities such as diabetes and hypertension was similar by HIV serostatus. A greater proportion of HIVþ than HIVÀ participants were nonwhite, HCV-infected as well as current smokers.
Among the HIVþ men at index visit, the median CD4 þ cell count was 490 cells/ml, median HIV-1 RNA level was 342 copies/ml, and 10% had a clinical AIDS diagnosis prior to the index visit. At the last follow-up visit, 798 (61%) HIV-infected men were using TDF, and the median [interquartile range (IQR)] cumulative TDF use at last follow-up visit was 3.4 (0.3-7.2) years. The proportion of men using protease inhibitor at the last follow-up visit was 44% (N ¼ 581); median cumulative protease inhibitor use was 4.5 (IQR 0.3-9.4) years. . When stratified by age categories and HIV serostatus, the incidence rates of fragility fracture in HIVÀ were 2.9/1000 person-years in both the 40-49 and 50-59 year old groups and 5.1/1000 person-years in the group aged at least 60 years. Within HIVþ the incidence rate of fragility fracture increased from 2.6 to 6.3 and 7.6 per 1000 person-years in those aged 40-49, 50-59 and at least 60 years, respectively [ Table 2 (Supplementary, http://links.lww.com/QAD/B83) and Fig. 1 ]. There was no evidence of an interaction between HIV and age on fragility fracture (P ¼ 0.135).
Incidence of all fractures
The unadjusted risk of fragility fracture is shown in Table  3 Adjusted incidence rate ratio of all fractures and osteoporotic fractures in the HIV-infected cohort was estimated using Poisson regression model adjusting for age, BMI, race, eGFR, hypertension, diabetes, HCV-infection, tobacco smoking, alcohol use, CD4 þ cell count, viral load, AIDS history, 5-year cumulative TDF and PI use. Multiple imputation was carried out to fill in missing covariates. Bold values indicate P < 0.05. 95% CI, 95% confidence intervals; ART, antiretroviral therapy; DXA, dual-energy X-ray absorptiometry; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; HR, hazard ratio; IRR, Incident rate ratio; LL, lower limit; PI, protease inhibitor; TDF, tenofovir disoproxil fumerate; UL, upper limit. 400 copies/ml nor VCY were associated with higher incidence of fragility fractures [ Table 2 and Table 4 (Supplementary, http://links.lww.com/QAD/B83)]. Cumulative protease inhibitor use and cumulative TDF use were not associated with incident fragility fracture.
Discussion
In this cohort of MSM, we found that the fracture incidence increased with older age among both the HIVþ and HIVÀ participants; however, the fracture rate was higher in HIVþ aged 50-59 years compared with HIVÀ men of the same age. Our findings support the Infectious Diseases Society of America [19] and the European AIDS Clinical Society guidelines, reinforcing the importance of baseline bone densitometry dualenergy X-ray absorptiometry (DXA) screening for osteoporosis in HIV-infected men aged 50 years and above.
Fracture rates are higher among HIVþ compared with HIVÀ persons and increase proportionally with advancing age [28] . Among HIVþ persons in the HIV Outpatient Study, age more than 47 years was associated with increased fracture risk even after adjusting for multiple factors (HR 1.43 per 10 years for fragility fractures) [3] . In a population-based retrospective cohort study conducted in Spain, age stratified analyses demonstrated significant associations between HIV infection and fractures only in the HIVþ participants aged 59 years and above [29] . In the Veterans Aging Cohort Study Virtual Cohort (VACS-VC), there was a significant increase in the risk of fragility fracture with advancing age (HR 1.52 per 10 year increments) even after adjustment for multiple factors [11] . In our analysis, we found an increase in the incidence of all fractures and fragility fractures among HIVþ men starting at age 50. The fracture incidence rates we observed in MACS are somewhat different from those reported by others. In the Danish population, Hansen et al. reported a fracture incidence of 21 per 1000 personyears in the HIVþ and 13.5 per 1000 person-years in the HIVÀ. The incidence of fragility fracture among male veterans from VACS-VC was slightly lower, with 2.5 per 1000 person-years for HIVþ and 1.9 per 1000 personyears for HIVÀ persons. It is possible that our study population is unique in several aspects. In addition, the HIVÀ comparison group in the MACS is drawn from a population of MSM with very similar underlying risk factors to the HIVþ men, which is a major strength of our study.
Amongst several risk factors investigated, we found that hypertension was an independent predictor of all fractures with similar trends for the outcome of fragility fracture. Although data are sparse, there is some clinical evidence, mainly from observational studies, supporting an increased fracture risk in hypertensive people. Although some studies found only an increased risk of vertebral fractures in hypertensive patients [30] , others demonstrated a higher risk of any fracture [31] . An observational cohort study of Australians aged 50 years and above, found hypertension to be associated with an increased risk of fragility fractures in women but not in men [32] . Although the exact underlying mechanism remains uncertain, several potential explanations for the effect of hypertension on fracture risk exist. High BP has been associated with increased urinary calcium loss, secondary hyperparathyroidism and loss of calcium from bone [33] . In addition, hypertensive patients tend to be older and more prone to falls [34] . Furthermore, antihypertensive medications, apart from increasing the risk of fall injuries by causing or worsening orthostatic hypotension [35] , may also exert direct effects on bone [36] . Data on falls, frailty and markers of calcium metabolism were not available for the entire period covered by this analysis; therefore, we could not assess potential mechanisms for the observed hypertension/fracture association.
Low eGFR has been associated with increased fracture risk [37] . In our study, eGFR was no longer associated with fractures after adjusting for age, BMI and hypertension. This finding suggests that the association of eGFR and fracture may be because of other confounders or that the lack of an association was due to the small number of participants with moderate and severe kidney impairment in our study population. Several studies evaluating the association between CKD and fractures have reported increased fracture risk only with moderate to severe CKD [38] .
We found no associations between the incidence of fractures and other factors like BMI, race, current smoking, moderate-heavy or binge alcohol consumption, diabetes or HCV. Several studies have reported significantly higher rates of fractures in patients with HIV and HCV coinfection compared with those with HIV monoinfection [3, 39] , whereas others have not reproduced this finding [9] . HCV has been shown to be a marker of intravenous drug use [40] , and the higher risk of fracture in HIV-HCV coinfected patients has thus been attributed to direct consequences of drug use such as higher risk of trauma, falls and nutritional deficiencies [17] . The small percentage of MACS participants reporting use of intravenous drugs (2%) might explain why no association was detected in our analysis.
The role of HIV-specific factors in fracture risk remains uncertain. Although no association with ART exposure has been reported in several studies [3, 9] , others found higher rates of fractures associated with ART exposure [11, 17] . Using data from the ACTG Longitudinal-Linked Randomized Trial, Yin et al. [41] found a significantly higher fracture rate in the first 2 years after ART initiation that declined in subsequent years. We found that current ART use was associated with an increased risk of fracture. These findings are consistent with results from the Strategies for Management of Antiretroviral Therapy substudy in which continuous administration of ART results in losses in BMD, whereas ART interruption was associated with BMD stabilization or increases [16] . Taken together, these findings suggest that ART treatment, regardless of the ART regimens used, has detrimental effects on bone health.
Specific ART medications, including TDF and protease inhibitors, have been associated with loss of BMD and increased fracture risk in some [11, 18, 42] , but not all studies [9] . In our multivariate analysis, neither cumulative protease inhibitor use, nor TDF was associated with increased incidence of all or fragility fractures, although our study was not specifically designed to assess effects of specific medications, in that the relatively small number of events may have limited the statistical power to detect associations.
We found no associations between CD4 þ T-cell count and history of AIDS with fracture risk. Although some studies have reported increased fracture rates in individuals with low CD4 þ T-cell count [3] and a history of AIDS-defining illness, others have not [17, 42] . We did, however, find an association between cumulative viremia and fracture independent of receiving ART. This finding suggests that the legacy of poorly controlled HIV infection in the past may have important future clinical consequences with respect to fracture risk and that patients who have a long history of uncontrolled viremia may benefit from more aggressive osteoporosis screening and treatment.
Our study has several strengths including a relatively large sample size, incidence of all fractures and fragility fractures as main outcomes and data on several fracture risk factors. In addition, the MACS includes HIVÀ men with similar risk behaviors as the HIVþ, and regardless of HIV serostatus, men were followed semiannually and completed the same fracture questionnaires. We performed risk analyses stratified by age and HIV serostatus allowing us to demonstrate age strata specific increases in fracture rates. Furthermore, data on HIV-specific risk factors were collected at semiannual visits.
We also recognize several limitations. Fractures were selfreported without confirmation by medical chart review or radiographic evaluation although fractures are adverse events that patients tend to remember and reliably selfreport [43] . We were not able to determine specifically whether fractures occurred in the setting of major trauma, which might have resulted in the overestimation of fragility fractures. In addition, as histories of fractures were retrospectively collected through questionnaires, recollection bias might be an important limitation. Furthermore, we have no data on calcium and vitamin D supplementation, and we did not account for drugs that may have an impact on bone health, such as the proton pump inhibitors. Specific information on testosterone and glucocorticoid use was introduced in the MACS questionnaire only recently. Missing data were an issue particularly for variables only later routinely collected in the MACS, but we addressed this limitation by using multiple imputation analysis to fill in missing covariates data.
In conclusion, we found that HIVþ MACS participants had higher incidence of all fractures and fragility fractures compared with the HIVÀ controls and that the rate of fracture was higher among the HIVþ men aged 50-59 years compared with HIVÀ participants of similar age. Our findings support the current available guidelines recommending baseline DXA screening for HIVþ men starting at age 50. Hypertension remained consistently associated with higher incidence of all fractures even after adjustment for additional fracture risks. To our knowledge, this is the first report in which an association between hypertension and increased fracture incidence among HIVþ persons has been noted. The exact mechanism underlying the association between BMD, fracture, hypertension and antihypertensive agents remains largely unknown and warrants further exploration.
